GlassScriptPhysician profile
Paige Jennings
NPI 1316956428
$1,464.54
in general payments reported to CMS, 2019-2025
24 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $164 · 2021: $121 · 2022: $275 · 2023: $372 · 2024: $183 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $294.34 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $173.05 | 2019-2025 | |
| Pfizer INC. | $140.60 | 2019-2024 | |
| Abbvie INC. | $131.73 | 2019-2023 | |
| Hologic Sales and Service, LLC | $87.61 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Organon LLC | $83.93 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $74.87 | 2020-2023 | Slynd |
| Therapeuticsmd, INC. | $67.53 | 2019-2021 | |
| Coopersurgical, INC. | $59.43 | 2022-2024 | Paragard T 380a, Endosee |
| Merck Sharp & Dohme LLC | $48.04 | 2020-2022 | |
| Evofem Biosciences, INC. | $39.75 | 2021-2023 | Phexxi |
| Astellas Pharma US INC | $36.66 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $33.44 | 2021 | |
| Daiichi Sankyo INC. | $32.33 | 2019 | |
| Sage Therapeutics, LLC | $23.52 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.22 | 2019-2020 | |
| Scynexis, INC. | $18.32 | 2022 | |
| Ibsa Pharma INC. | $17.89 | 2023 | Tirosint, Licart |
| Lilly USA, LLC | $16.95 | 2020 | |
| Duchesnay USA Incorporated | $16.90 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.64 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.51 | 2019 | |
| Avion Pharmaceuticals | $14.28 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.